BocaBio has been involved in solving the worlds pandemic concerns for three decades. We provided vital research support to the Dx and Pharma communities during the Zika outbreak of 2016. Little is known about the research that we continued to support on Zika even now in 2020. With the COVID-19 pandemic in full swing, BocaBio's entire team has been allocated to tackle this problem. We have focused our full capabilities as a hybrid CRO in the following ways to enhance all stages of diagnostic development as well as therapeutics.
- Providing biological specimens critical for discovery R&D for Dx and therapeutic development, through our Biobanx division
- Offer critically needed COVID-19 testing for PCR as well as serology through our CLIA/CAP accredited BocaBio Reference Lab division
- Prospectively collecting both confirmed positive and negative COVID-19 patients for clinical trials support of Dx and Pharma development
As always, our entire Bocabio family stands vigilant, together, behind the scenes, doing our part to serve our community.
Be safe, help others
Joseph Lawrence Mauro Chief Vision Officer
COVID-19 panels and inventory
Boca Biolistics is announcing the launch of the BBL SARS-CoV-2 Validation Panel! The BBL SARS-CoV-2 panel will consist of non-contrived native human material, 30 positive and 30 negative NP/OP specimens characterized and designed for use on the Hologic Panther Fusion SARS-CoV-2 Test. Panel will be available mid-April. Due to limited stocks, contact your BBL sales rep for more information.
Accepting pre-orders, call us now for availability!
NP/OP swabs, serum and plasma laboratory remnant specimens, received and processed under BBL's IRB approved de-linked proprietary process.
BBL announces the BBL SARS-CoV-2 validation panel for accelerated SARS-CoV-2 assay onboarding. Our propriety panel is comprised of native, non-contrived specimens NP/OP specimens and performed on the Hologic Panther Fusion platform.
We are also in development of additional panels for NP/OP specimens as well as serum and plasma for serological assay on-boarding.
Custom panels are also available for manufacture upon request.
Boca Biolistics is launching a domestic and ex-US prospective clinical sample collection from subjects that have been diagnosed with COVID-19 and have an acute or convalescent infection.
The following sample matrices will be collected per subject:
Data obtained from subjects will include the following:
COVID-19 NAT to be performed at Boca Biolistics Reference Lab.
Study to launch late April 2020. Allocation of sample volume will be limited.